Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma

被引：0
|
作者：
Coffey, David G. [1 ,2 ]
Landgren, Ola [3 ]
Xu, Yuexin [1 ]
Kazandjian, Dickran [4 ]
Pugh, Trevor J. [5 ]
Gnjatic, Sacha [6 ]
Warren, Edus H. [1 ,2 ]
Green, Damian J. [1 ,2 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA
[2] Univ Washington, Dept Med, Seattle, WA USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA
[4] NCI, Ctr Canc Res, Lymphoid Malignancies Branch, Multiple Myeloma Program,NIH, Bethesda, MD 20892 USA
[5] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Icahn Sch Med Mt Sinai, Human Immune Monitoring Ctr, New York, NY 10029 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126222
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4367
引用
收藏
页数：3
相关论文
共 50 条
  • [21] MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance
    Davis, Lorraine N.
    Walker, Zachary J.
    Reiman, Lauren T.
    Parzych, Sarah E.
    Stevens, Brett M.
    Jordan, Craig T.
    Forsberg, Peter A.
    Sherbenou, Daniel W.
    CLINICAL CANCER RESEARCH, 2024, 30 (14) : 3023 - 3035
  • [22] Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma
    Ntanasis-Stathopoulos, Ioannis
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    CANCER JOURNAL, 2019, 25 (01): : 2 - 10
  • [23] FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma
    Kumar, S
    Raje, N
    Hideshima, T
    Ishitsuka, K
    Podar, K
    Le Gouille, S
    Chauhan, D
    Richardson, P
    Munshi, NC
    Anderson, K
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 132 (06) : 698 - 704
  • [24] Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations
    Hussein, Mohamad A.
    THROMBOSIS AND HAEMOSTASIS, 2006, 95 (06) : 924 - 930
  • [25] Roles of noncoding RNAs in drug resistance in multiple myeloma
    Li Jingwen
    Zou Jing
    Wan Xiaoyue
    Sun Chunyan
    Chu Zhangbo
    Hu Yu
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (11) : 7681 - 7695
  • [26] Integrin-mediated drug resistance in multiple myeloma
    Damiano, JS
    Dalton, WS
    LEUKEMIA & LYMPHOMA, 2000, 38 (1-2) : 71 - 81
  • [27] The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
    Faict, Sylvia
    Oudaert, Inge
    D'Auria, Ludovic
    Dehairs, Jonas
    Maes, Ken
    Vlummens, Philip
    De Veirman, Kim
    De Bruyne, Elke
    Fostier, Karel
    Vande Broek, Isabelle
    Schots, Rik
    Vanderkerken, Karin
    Swinnen, Johannes, V
    Menu, Eline
    CANCERS, 2019, 11 (12)
  • [28] Drug resistance and minimal residual disease in multiple myeloma
    Gozzetti, Alessandro
    Ciofini, Sara
    Sicuranza, Anna
    Pacelli, Paola
    Raspadori, Donatella
    Cencini, Emanuele
    Tocci, Dania
    Bocchia, Monica
    CANCER DRUG RESISTANCE, 2022, 5 (01) : 171 - 183
  • [29] The link between drug resistance in Multiple Myeloma and Hypoxia
    Aouali, Nassera
    Bosseler, Manon
    Marani, Vanessa
    Berchem, Guy
    Janji, Bassam
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 : S40 - S40
  • [30] Targeting Neddylation to Overcome Drug Resistance in Multiple Myeloma
    Thomas, Gregory S.
    Huang, Junwei
    Zhou, Yi
    Gu, Zhimin
    Yang, Ye
    Xu, Hongwei
    Tricot, Guido J.
    Zhan, Fenghuang
    BLOOD, 2015, 126 (23)
12345